Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model.

Ahmed AU, Rolle CE, Tyler MA, Han Y, Sengupta S, Wainwright DA, Balyasnikova IV, Ulasov IV, Lesniak MS.

Mol Ther. 2010 Oct;18(10):1846-56. doi: 10.1038/mt.2010.131. Epub 2010 Jun 29.

2.

A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.

Ahmed AU, Tyler MA, Thaci B, Alexiades NG, Han Y, Ulasov IV, Lesniak MS.

Mol Pharm. 2011 Oct 3;8(5):1559-72. doi: 10.1021/mp200161f. Epub 2011 Jun 30.

3.

Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors.

Hakkarainen T, Särkioja M, Lehenkari P, Miettinen S, Ylikomi T, Suuronen R, Desmond RA, Kanerva A, Hemminki A.

Hum Gene Ther. 2007 Jul;18(7):627-41.

PMID:
17604566
4.

Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells.

Melen GJ, Franco-Luzón L, Ruano D, González-Murillo Á, Alfranca A, Casco F, Lassaletta Á, Alonso M, Madero L, Alemany R, García-Castro J, Ramírez M.

Cancer Lett. 2016 Feb 28;371(2):161-70. doi: 10.1016/j.canlet.2015.11.036. Epub 2015 Dec 3.

PMID:
26655276
5.

Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth.

Hsiao WC, Sung SY, Liao CH, Wu HC, Hsieh CL.

Mol Pharm. 2012 May 7;9(5):1396-408. doi: 10.1021/mp200649g. Epub 2012 Apr 16.

PMID:
22480282
6.

Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.

Hammer K, Kazcorowski A, Liu L, Behr M, Schemmer P, Herr I, Nettelbeck DM.

Int J Cancer. 2015 Aug 15;137(4):978-90. doi: 10.1002/ijc.29442. Epub 2015 Feb 20.

PMID:
25604186
7.

A specific subpopulation of mesenchymal stromal cell carriers overrides melanoma resistance to an oncolytic adenovirus.

Bolontrade MF, Sganga L, Piaggio E, Viale DL, Sorrentino MA, Robinson A, Sevlever G, García MG, Mazzolini G, Podhajcer OL.

Stem Cells Dev. 2012 Sep 20;21(14):2689-702. doi: 10.1089/scd.2011.0643. Epub 2012 May 14.

8.

IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells.

Chinnadurai R, Copland IB, Patel SR, Galipeau J.

J Immunol. 2014 Feb 15;192(4):1491-501. doi: 10.4049/jimmunol.1301828. Epub 2014 Jan 8.

9.

[Synergistic immunomodulatory effects of interferon-gamma and bone marrow mesenchymal stem cells].

Liang C, Chen SL, Wang M, Zhai WJ, Zhou Z, Pang AM, Feng SZ, Han MZ.

Zhonghua Xue Ye Xue Za Zhi. 2013 Mar;34(3):213-6. doi: 10.3760/cma.j.issn.0253-2727.2013.03.007. Chinese.

PMID:
23683418
10.

Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: effect of interferon-γ and tumor necrosis factor-α stimulation.

Cuerquis J, Romieu-Mourez R, François M, Routy JP, Young YK, Zhao J, Eliopoulos N.

Cytotherapy. 2014 Feb;16(2):191-202. doi: 10.1016/j.jcyt.2013.11.008.

PMID:
24438900
11.

Adenoviral transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantation.

Treacy O, Ryan AE, Heinzl T, O'Flynn L, Cregg M, Wilk M, Odoardi F, Lohan P, O'Brien T, Nosov M, Ritter T.

PLoS One. 2012;7(8):e42662. doi: 10.1371/journal.pone.0042662. Epub 2012 Aug 6.

12.
13.

Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.

Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, Kim H, Cho S, Sohn JH, Kim GE, Yun CO.

Gene Ther. 2006 Jul;13(13):1010-20. Epub 2006 Mar 9.

PMID:
16525479
14.

Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus.

Steel JC, Morrison BJ, Mannan P, Abu-Asab MS, Wildner O, Miles BK, Yim KC, Ramanan V, Prince GA, Morris JC.

Virology. 2007 Dec 5;369(1):131-42. Epub 2007 Aug 28.

15.

Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro.

Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, Pistoia V, Martin I, Tyndall A.

Rheumatology (Oxford). 2007 Mar;46(3):403-8. Epub 2006 Aug 18.

16.

Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.

Ren Z, Ye X, Fang C, Lu Q, Zhao Y, Liu F, Liang M, Hu F, Chen HZ.

Cancer Biol Ther. 2008 Feb;7(2):191-95. Epub 2007 Nov 3.

PMID:
18073525
17.

Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.

Lee YS, Kim JH, Choi KJ, Choi IK, Kim H, Cho S, Cho BC, Yun CO.

Clin Cancer Res. 2006 Oct 1;12(19):5859-68.

18.

The use of hypoxic cultured mesenchymal stem cell for oncolytic virus therapy.

Huang YF, Chen MJ, Wu MH, Hung SC.

Cancer Gene Ther. 2013 May;20(5):308-16. doi: 10.1038/cgt.2013.22. Epub 2013 Apr 26.

PMID:
23618949
19.

Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas.

Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, Bogler O, Andreeff M, Lang FF.

Cancer Res. 2009 Dec 1;69(23):8932-40. doi: 10.1158/0008-5472.CAN-08-3873. Epub 2009 Nov 17.

20.

Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity.

Castleton A, Dey A, Beaton B, Patel B, Aucher A, Davis DM, Fielding AK.

Blood. 2014 Feb 27;123(9):1327-35. doi: 10.1182/blood-2013-09-528851. Epub 2013 Dec 17.

Items per page

Supplemental Content

Write to the Help Desk